Hookipa Pharma Stock Price, News & Analysis

HOOKIPA Pharma Inc. (NASDAQ: HOOK) has announced that a Trial in Progress poster detailing its ongoing Phase 1/2 study of HB-300 for metastatic castration-resistant prostate cancer has been accepted for presentation at the ASCO Annual Meeting from June 2-6, 2023. The presentation will provide insights into HB-300, a novel immunotherapy utilizing an arenavirus platform, aimed at enhancing immune response specifically against prostate cancer. The details of the presentation include an abstract and poster session scheduled for June 3, 2023. HB-300 aims to elicit robust T cell responses and has shown potential in preclinical studies. The full abstract will be available on May 25, 2023, at 5:00 pm ET.

HOOKIPA Pharma Inc. (NASDAQ: HOOK), a biopharmaceutical company specializing in immunotherapies, announced its participation in investor meetings at the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 25-26, 2023. This event highlights HOOKIPA's commitment to advancing its proprietary arenavirus platform aimed at fighting serious diseases.

HOOKIPA is focused on developing therapies that enhance T cell responses to combat various cancers, including Human Papillomavirus 16-positive cancers and prostate cancers. Additionally, the company collaborates with Roche on treatments for KRAS-mutated cancers and aims to create functional cures for HBV and HIV alongside Gilead.

HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced the granting of non-statutory options for 50,000 shares of Common Stock to a new employee. This decision, approved by the Compensation Committee, is in line with Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee's acceptance of employment. The exercise price is set at $1.00 per share, with a ten-year term and a vesting schedule that includes 25% vesting on the one-year anniversary and the remainder vesting quarterly over three years. HOOKIPA is a biopharmaceutical company focusing on immunotherapies developed from its proprietary arenavirus platform, targeting various cancers and collaborating with Roche and Gilead for future treatments.

HOOKIPA Pharma reported financial results and corporate updates for 2022, highlighting substantial progress in developing immunotherapeutics. The company strengthened its cash position to $113.4 million as of December 31, 2022, with an additional $15.0 million from collaboration milestones in early 2023. HOOKIPA's lead candidate, HB-200, advanced to Phase 2 trials in head and neck cancers, while its prostate cancer program, HB-300, is open for enrollment. The KRAS program (HB-700) achieved its first milestone payment from Roche in February 2023. Revenue decreased to $14.2 million in 2022, down from $18.4 million in 2021, primarily due to lower reimbursements from the Gilead collaboration.

HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced the appointment of Terry Coelho to its Board of Directors effective April 3, 2023. With over 35 years of experience, including roles in finance and business development at CinCor Pharma and Novartis, Coelho is expected to strengthen HOOKIPA's leadership as it advances its immunotherapeutic pipeline targeting oncology and infectious diseases. CEO Joern Aldag emphasized her strategic insights will be valuable for the company’s ongoing clinical programs. HOOKIPA is known for its proprietary arenavirus platform aimed at developing novel therapeutics for serious diseases.

HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced plans to release its fourth quarter and full year 2022 financial results on March 15, 2023, before the market opens. The company will host a live conference call at 8:30 AM ET to discuss these results and provide a corporate update. HOOKIPA specializes in developing immunotherapeutics based on its proprietary arenavirus platform, targeting cancers and viral diseases such as HBV and HIV. The company collaborates with notable partners including Roche and Gilead. For access details, participants can find the webcast link on HOOKIPA's investor relations page.

HOOKIPA Pharma Inc. (NASDAQ: HOOK) has announced a $10 million non-dilutive milestone payment from Roche for the development of HB-700, an immunotherapy for KRAS-mutated cancers. This payment marks the initiation of the HB-700 manufacturing process in preparation for a Phase 1 clinical trial. HOOKIPA plans to file an Investigational New Drug Application (IND) with the FDA in the first half of 2024. The collaboration allows HOOKIPA to pursue further milestones totaling approximately $930 million, plus royalties, for this and another undisclosed program.

HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in the virtual SVB Securities Global Biopharma Conference from February 14-16, 2023. The company plans to deliver a corporate presentation on February 14, 2023, at 10:00 AM EST. Interested parties can access the live webcast and archived replay through the Investors & Media section of HOOKIPA’s website.

HOOKIPA is focused on developing innovative immunotherapies utilizing its proprietary arenavirus platform. Their pipeline includes therapies targeting Human Papillomavirus 16-positive cancers and prostate cancers, along with collaborations with Roche and Gilead on cancer and viral infections.